IP Library Granted Patent US 6,921,825
Granted Patent B2
US 6,921,825 · App. 10/134,219 · Granted Jul 26, 2005

Adenosine A3 receptor modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,921,825
App. No.
10/134,219
Granted
Jul 26, 2005
Kind
B2
Abstract

The compounds of the following formula: wherein R, R 2 , R 3 and A have the meanings given in the specification, are endowed with selective A 3 adenosine receptor antagonist activity. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A 3 receptor, or can be used in a diagnostic application to determine the relative binding of other compounds to the A 3 receptor. The compounds can be labeled, for example with fluorescent or radiolabels, and the labels used in vivo or in vitro to determine the presence of tumor cells which possess a high concentration of adenosine A 3 receptors.

Claims (20)

1. A compound of the following formula:

wherein:

A is imidazole, pyrazole, or triazole;

R 2 is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;

R 3 is furan; and

R 4 is hydrogen, alkyl, amino, substituted alkyl, alkyl substituted amino, alkyl di-substituted amino, alkenyl, aralkyl, substitute aralkyl, heteroaryl, substituted heteroaryl, heterocycle, aryl, substituted aryl, sulfonyl or substituted sulfonyl; and

pharmaceutically acceptable salts thereof.

2. The compound of claim 1 wherein R 2 is selected from the group consisting of hydrogen, alkyl, alkenyl and aryl.

3. The compound of claim 1 wherein A is a triazolo ring.

4. The compound of claim 1 wherein A is a pyrazolo ring.

5. A compound of the following formula:

wherein:

A is imidazole, pyrazole, or triazole;

R 2 is hydrogen, alkyl, substituted alkyl, alkenyl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl or aryl;

R 3 is furan; and

R 6 is heteroaryl or substituted heteroaryl; and

pharmaceutically acceptable salts thereof.

6. The compound of claim 5 wherein R 2 is selected from the group consisting of hydrogen, alkyl, alkenyl and aryl.

7. The compound of claim 5 wherein A is a triazolo ring.

8. The compound of claim 5 wherein A is a pyrazolo ring.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Feb 3, 2011
From: CREDIT SUISSE AG
To: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
Reel/Frame 025738/0132 →
SECURITY AGREEMENT Recorded May 13, 2010
From: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
To: CREDIT SUISSE AG
Reel/Frame 025703/0628 →
RELEASE OF SECURITY INTEREST Recorded May 11, 2010
From: KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC.
To: CREDIT SUISSE AG
Reel/Frame 024369/0022 →
SECURITY AGREEMENT Recorded Dec 30, 2008
From: KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC.
To: CREDIT SUISSE, AS AGENT
Reel/Frame 022034/0870 →